Sarepta Therapeutics 주식 (NASDAQ: SRPT)

에 대한 최신 뉴스 Sarepta Therapeutics (NASDAQ:SRPT) 주식

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Nvidia, AMD, Archer Aviation, Rocket Lab, And Tesla: Why Are These 5 Stocks On Investors' Radars Today

Equities

News

Markets

NVDA

QBTS

SRPT

TSLA

화요일(18일) 미국 증시는 투자자들이 연준의 금리 결정을 기다리면서 하락했다. 화요일 주목받은 주식: 엔비디아, 메타, 사렙타, D-웨이브 및 테슬라

화요일 주목받은 주식: 엔비디아, 메타, 사렙타, D-웨이브 및 테슬라

The Archer Aviation Trade

Mid Cap

Movers

Trading Ideas

ACHR

ARWR

BHVN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IREN

JOBY

SOUN

SRRK

URBN

이 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아처 에비에이션(NYSE:ACHR) 주식은 지난주 65.57% 급등했다.

아처 및 어번 아웃피터스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (11월 25일-29일)

rivian shutter2

Large Cap

CPRT

ESTC

EXAS

MRNA

RIVN

RKLB

SNAP

ULTA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 리비안 오토모티브(NASDAQ:RIVN)의 주식이 22.06% 급등했다. 이는 회사가 66억 달러의 에너지부(DOE)의 대출 약정을 확보한 후 발생한 일이다.

리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler cut Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) price target from $182 to $110. Piper Sandler analyst Biren Amin maintained an Overweight rating. Sarepta Therapeutics shares closed at $53.79 on Thursday. See how other analysts view this stock.</li>
<li>Wells Fargo slashed the price target for AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) from $194 to $176. Wells Fargo analyst Colin Langan maintained an Equal-Weight rating. AutoNation shares closed at $165.78 on Thursday. See how other analysts view this stock.</li>
<li>Barclays cut Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $180 to $125. Barclays analyst Raimo Lenschow maintained an Overweight rating. Datadog shares closed at $91.18 on Thursday. See how other analysts view this stock.</li>
<li>Ascendiant Capital slashed the price target for BioSig Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) from $2.75 to $2.5. Ascendiant Capital analyst Edward Woo maintained a Buy rating. BioSig Technologies shares closed at $0.5644 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Snap-on Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) from $349 to $320. Baird analyst Luke Junk maintained a Neutral rating. Snap-on shares closed at $305.44 on Thursday. See how other analysts view this stock.</li>
<li>Rosenblatt increased Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $1,494 to $1,514. Rosenblatt analyst Barton Crockett maintained a Buy rating. Netflix shares settled at $973.03 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) price target from $74 to $78. JP Morgan analyst Andrea Teixeira maintained an Overweight rating. Coca-Cola shares closed at $73.00 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Seaport Global cut Minerals Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTX#NYSE">MTX</a>) price target from $92 to $80. Seaport Global analyst Michael Harrison maintained a Buy rating. Minerals Technologies shares closed at $56.71 on Thursday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed the price target for Westamerica Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WABC#NASDAQ">WABC</a>) from $54 to $50. Piper Sandler analyst Andrew Liesch maintained a Neutral rating. Westamerica shares settled at $45.97 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity slashed Kopin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) price target from $2.5 to $2.25. Canaccord Genuity analyst George Gianarikas maintained a Buy rating. Kopin shares closed at $0.9054 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36-1024x594.png" alt="" class="wp-image-879858" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21100201/image-36.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Analyst Ratings

BSGM

DDOG

KOPN

NFLX

WABC

Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $182 to $110.

Piper Sandler Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $110

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$450.00</td>
<td>$52.0K</td>
<td>100</td>
<td>4.3K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$33.3K</td>
<td>3.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$134.3K</td>
<td>992</td>
<td>550</td>
</tr>
<tr>
<td>BHVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$17.50</td>
<td>$26.6K</td>
<td>20</td>
<td>401</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$780.00</td>
<td>$25.9K</td>
<td>1.0K</td>
<td>384</td>
</tr>
<tr>
<td>SLNO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$25.0K</td>
<td>4.4K</td>
<td>262</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>897</td>
<td>233</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$70.00</td>
<td>$61.9K</td>
<td>336</td>
<td>39</td>
</tr>
<tr>
<td>MTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1180.00</td>
<td>$58.8K</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$75.00</td>
<td>$29.0K</td>
<td>10</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 100 contract(s) at a $450.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $52.0K, with a price of $520.0 per contract. There were 100 open contracts at this strike prior to today, and today 4332 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option sweep that happens to be bullish, expiring in 273 day(s) on January 16, 2026. This event was a transfer of 34 contract(s) at a $50.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $33.3K, with a price of $980.0 per contract. There were 3960 open contracts at this strike prior to today, and today 1145 contract(s) were bought and sold. 
• For BNTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), we notice a call option sweep that happens to be bearish, expiring in 28 day(s) on May 16, 2025. This event was a transfer of 363 contract(s) at a $105.00 strike. This particular call needed to be split into 52 different trades to become filled. The total cost received by the writing party (or parties) was $134.3K, with a price of $370.0 per contract. There were 992 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• Regarding BHVN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), we observe a put option trade with bearish sentiment. It expires in 28 day(s) on May 16, 2025. Parties traded 140 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $190.0 per contract. There were 20 open contracts at this strike prior to today, and today 401 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be bullish, expiring in 1 day(s) on April 17, 2025. This event was a transfer of 4 contract(s) at a $780.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $6480.0 per contract. There were 1032 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• Regarding SLNO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>), we observe a call option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 50 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 4483 open contracts at this strike prior to today, and today 262 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 637 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $1050.0 per contract. There were 897 open contracts at this strike prior to today, and today 233 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a put option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 38 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $61.9K, with a price of $1630.0 per contract. There were 336 open contracts at this strike prior to today, and today 39 contract(s) were bought and sold. 
• Regarding MTD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), we observe a call option trade with bearish sentiment. It expires in 182 day(s) on October 17, 2025. Parties traded 12 contract(s) at a $1180.00 strike. The total cost received by the writing party (or parties) was $58.8K, with a price of $4900.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we notice a call option trade that happens to be neutral, expiring in 336 day(s) on March 20, 2026. This event was a transfer of 5 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $5814.0 per contract. There were 10 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BNTX

SLNO

10 Health Care Stocks Whale Activity In Today's Session

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and maintains $75 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $75 Price Target

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5
–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3
–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Data expected for SRP-9003 for LGMD2E/R4 by mid-2025
Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on limb-girdle muscular dystrophy (LGMD) subtypes 2C/R5, 2D/R3, and 2E/R4.
<ul>
<li>SRP-9005 for LGMD type 2C/R5: Following input from the U.S. Food and Drug Administration (FDA), Office of Therapeutic Products (OTP), Sarepta is cleared to proceed with dosing in Study SRP-9005-101 (COMPASS) in the U.S. COMPASS is a first-in-human clinical study of SRP-9005, an investigational gene therapy for LGMD type 2C/R5, or gamma-sarcoglycanopathy.</li>
<li>SRP-9004 for LGMD type 2D/R3: Enrollment and dosing is complete in Study SRP-9004-102 (DISCOVERY).DISCOVERY is a phase 1, proof-of-concept study evaluating safety and expression of the alpha-sarcoglycan protein after treatment with SRP-9004, an investigational gene therapy for the treatment of LGMD type 2D/R3, or alpha-sarcoglycanopathy.</li>
<li>SRP-9003 for LGMD type 2E/R4: Enrollment and dosing is complete in Study SRP-9003-301 (EMERGENE). EMERGENE is a phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec) for the treatment of LGMD type 2E/R4, or beta-sarcoglycanopathy. EMERGENE is a global study and the primary endpoint is the biomarker expression of beta-sarcoglycan protein. A pre-Biologics License Application (BLA) meeting has occurred and the OTP has confirmed eligibility for the accelerated approval pathway for the program. Sarepta remains on track to submit a BLA to the U.S. FDA in the second half of 2025.</li>
</ul>

Sarepta Issues Update From Clinical Programs Focused On LGMD Subtypes 2C/R5, 2D/R3, And 2E/R4; FDA Confirmed That Screening, Dosing May Proceed In Study SRP-9005-101 For Lgmd2C/R5

Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $196 to $182.

Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $182

Wells Fargo analyst Yanan Zhu initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight rating and announces Price Target of $115.

Initiation

Wells Fargo Initiates Coverage On Sarepta Therapeutics with Overweight Rating, Announces Price Target of $115

In March,&nbsp;Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
The company reported a patient death following treatment with Elevidys, having suffered <a target="_blank" href="https://www.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" rel="noreferrer noopener">acute liver failure</a>.
Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.
On Wednesday, Sarepta and Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) temporarily <a target="_blank" href="https://www.duchenneuk.org/roche-temporarily-halts-clinic-studies/" rel="noreferrer noopener">halted</a> several clinical studies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43232532/sarepta-therapeutics-duchenne-gene-therapy-shows-sustained-benefits-and-disease-stabilization-at-two-years" rel="noreferrer noopener">Sarepta Therapeutics&#8217; Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years</a>
Roche, the company to which the treatment is licensed outside the US, has said that this was at the European Medicines Agency&#8217;s (EMA) request.
The companies have a therapeutic clinical hold on Study 104, Study 302, and Study 303 in the EU until the analysis of the cause of death is complete.
Roche is also pausing the enrollment and dosing of participants in the U.K. for its ENVOL study.
Patient safety monitoring for already enrolled participants and ongoing collection of data will continue.
In June 2024, the EMA validated and <a target="_blank" href="https://www.roche.com/investors/updates/inv-update-2024-06-24" rel="noreferrer noopener">initiated</a> a review of the marketing authorization application for Elevidys, a gene therapy for ambulatory patients aged 3-7 years old with Duchenne muscular dystrophy.
HC Wainwright upgraded Sarepta on Wednesday from Sell to Neutral, saying it is trading within a fair range.
Analyst Mitchell S. Kapoor still anticipates Elevidys revenue will fall short in the second half of 2025—especially after the recent patient death due to acute liver injury.
Kapoor sees a risk that Elevidys sales may decline faster than expected, possibly as early as Q2 2025, due to growing hesitation from doctors and patients regarding its safety. The treatment&#8217;s limited effectiveness heightens this concern.
The analyst maintains the price <a target="_blank" href="https://www.benzinga.com/quote/SRPT/analyst-ratings" rel="noreferrer noopener">forecast of $75 per share</a>.
Needham maintained Sarepta Therapeutics with a Buy, lowering the price forecast from $202 to $183.
Price Action: SRPT stock is down 6.68% at $58.30 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44631273/novartis-secures-third-fda-approval-for-its-kidney-disease-portfolio-in-one-year" target="_blank" rel="noreferrer noopener">Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year</a></li>
</ul>
Image via Sarepta Therapeutics

Analyst Color

Biotech

General

RHHBY

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

Investors with significant funds have taken a bearish position in Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in SRPT usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 9 options transactions for Sarepta Therapeutics. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 11% being bullish and 77% bearish. Of all the options we discovered, 8 are puts, valued at $395,971, and there was a single call, worth $61,500.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $60.0 for Sarepta Therapeutics over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Sarepta Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Sarepta Therapeutics's substantial trades, within a strike price spectrum from $60.0 to $60.0 over the preceding 30 days.
<h3>Sarepta Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743693968_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$2.5</td>
<td>$1.85</td>
<td>$1.9</td>
<td>$60.00</td>
<td>$95.0K</td>
<td>5.7K</td>
<td>5.2K</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.2</td>
<td>$60.00</td>
<td>$81.8K</td>
<td>5.7K</td>
<td>3.3K</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$12.7</td>
<td>$12.0</td>
<td>$12.3</td>
<td>$60.00</td>
<td>$61.5K</td>
<td>273</td>
<td>1</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$2.0</td>
<td>$1.95</td>
<td>$2.0</td>
<td>$60.00</td>
<td>$42.8K</td>
<td>5.7K</td>
<td>4.5K</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$1.7</td>
<td>$1.45</td>
<td>$1.7</td>
<td>$60.00</td>
<td>$42.1K</td>
<td>5.7K</td>
<td>5.4K</td>
</tr>
</tbody>
</table>

<h3>About Sarepta Therapeutics</h3>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
After a thorough review of the options trading surrounding Sarepta Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Sarepta Therapeutics</h3>
<ul>
<li>With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 27 days.</li>
</ul>
<h3>Professional Analyst Ratings for Sarepta Therapeutics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $106.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Sector Perform, adjusting the price target to $87. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Sarepta Therapeutics, which currently sits at a price target of $80. 
&#x2A; In a positive move, an analyst from HC Wainwright &amp; Co. has upgraded their rating to Neutral and adjusted the price target to $75. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Sarepta Therapeutics with a target price of $183. 
&#x2A; An analyst from Scotiabank downgraded its action to Sector Perform with a price target of $105. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In SRPT Options

WIIM

Sarepta Therapeutics shares are trading lower after Needham cut its price target on the stock from $202 to $183.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities cut Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $265 to $250. B of A Securities analyst Wamsi Mohan maintained a Buy rating. Apple shares closed at $223.89 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities raised the price target for The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from $180 to $185. Truist Securities analyst Bill Chappell maintained a Buy rating. Procter &amp; Gamble shares closed at $169.50 on Wednesday. <a href="https://www.benzinga.com/quote/PG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) price target from $212.5 to $186.5. JP Morgan analyst Andrew Dietrich maintained a Neutral rating. M&amp;T Bank shares closed at $179.71 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">view this stock</a>.</li>
<li>Morgan Stanley cut the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $530 to $300. Morgan Stanley analyst Simeon Gutman maintained an Overweight rating. RH shares closed at $249.35 on Wednesday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods cut the price target for nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) from $40 to $28. Keefe, Bruyette &amp; Woods analyst Ryan Tomasello maintained an Outperform rating. nCino shares closed at $22.59 on Wednesday. <a href="https://www.benzinga.com/quote/NCNO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group cut Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) price target from $40 to $27. Evercore ISI Group analyst Amit Daryanani downgraded the stock from Outperform to In-Line. Sensata Technologies shares settled at $24.61 on Wednesday. <a href="https://www.benzinga.com/quote/ST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) price target from $54 to $44. Jefferies analyst Sean Milligan maintained an Underperform rating. Enphase Energy shares closed at $62.52 on Wednesday. <a href="https://www.benzinga.com/quote/ENPH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised Sportradar Group AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) price target from $30 to $32. Canaccord Genuity analyst Michael Graham maintained a Buy rating. Sportradar shares closed at $22.20 on Wednesday.  <a href="https://www.benzinga.com/quote/SRAD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird slashed the price target for Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) from $46 to $43. Baird analyst Andrew Wittmann maintained a Neutral rating. Fluor shares settled at $37.22 on Wednesday. <a href="https://www.benzinga.com/quote/FLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) price target from $202 to $183. Needham analyst Gil Blum maintained a Buy rating. Sarepta Therapeutics shares closed at $62.47 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37-1024x590.png" alt="" class="wp-image-855474" style="width:516px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03091101/image-37.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

AAPL

ENPH

NCNO

SRAD

Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday

Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) has been analyzed by 18 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">5</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.72, a high estimate of $202.00, and a low estimate of $75.00. This current average has decreased by 7.25% from the previous average price target of $137.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1743681614_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Sarepta Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$183.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$87.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$99.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$161.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sarepta Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Sarepta Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Sarepta Therapeutics</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
<h3>Sarepta Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Sarepta Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 65.94%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sarepta Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 24.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 11.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sarepta Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.88, Sarepta Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)

Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and lowers the price target from $202 to $183.

Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $183

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor upgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sell to Neutral and maintained the price target of $75. Sarepta Therapeutics shares closed at $61.91 on Tuesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jimmy Bhullar upgraded Reinsurance Group of America, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) from Neutral to Overweight and raised the price target from $232 to $237. Reinsurance Group shares closed at $198.27 on Tuesday. <a href="https://www.benzinga.com/quote/RGA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Christopher Allen upgraded the rating for The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) from Neutral to Buy and lifted the price target from $85 to $102. Charles Schwab shares closed at $77.67 on Tuesday. <a href="https://www.benzinga.com/quote/SCHW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Will Nance upgraded Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) from Neutral to Buy and raised the price target from $246 to $260. Fiserv shares closed at $222.01 on Tuesday. <a href="https://www.benzinga.com/quote/FI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Bill Chappell upgraded The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) from Hold to Buy and maintained the price target of $70. Scotts Miracle Gro shares closed at $54.77 on Tuesday.  <a href="https://www.benzinga.com/quote/SMG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24-1024x595.png" alt="" class="wp-image-853451" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02103040/image-24.png 1086w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44605585/how-to-earn-500-a-month-from-conagra-brands-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Conagra Brands Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo via Shutterstock

Upgrades

SCHW

This Charles Schwab Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

HC Wainwright &amp; Co. analyst Mitchell Kapoor upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sell to Neutral and maintains the price target from $75 to $75.

HC Wainwright & Co. Upgrades Sarepta Therapeutics to Neutral, Maintains Price Target to $75

Sarepta Therapeutics shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform and lowered the price target from $161 to $87.

RBC Capital analyst Brian Abrahams downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Outperform to Sector Perform and lowers the price target from $161 to $87.

Downgrades

RBC Capital Downgrades Sarepta Therapeutics to Sector Perform, Lowers Price Target to $87

Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SRPT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Sarepta Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 54% leaning bullish and 18% bearish. Among these notable options, 4 are puts, totaling $282,850, and 7 are calls, amounting to $233,830.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $140.0 for Sarepta Therapeutics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Sarepta Therapeutics stands at 172.62, with a total volume reaching 607.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Sarepta Therapeutics, situated within the strike price corridor from $70.0 to $140.0, throughout the last 30 days.
<h3>Sarepta Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742584593_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.9</td>
<td>$30.3</td>
<td>$30.3</td>
<td>$100.00</td>
<td>$99.9K</td>
<td align="right">637</td>
<td align="right">63</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$30.4</td>
<td>$29.8</td>
<td>$30.4</td>
<td>$100.00</td>
<td>$72.9K</td>
<td align="right">637</td>
<td align="right">24</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$68.2</td>
<td>$64.2</td>
<td>$66.16</td>
<td>$140.00</td>
<td>$66.1K</td>
<td align="right">10</td>
<td align="right">10</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$24.6</td>
<td>$24.1</td>
<td>$24.3</td>
<td>$95.00</td>
<td>$43.7K</td>
<td align="right">142</td>
<td align="right">19</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$8.9</td>
<td>$8.4</td>
<td>$8.65</td>
<td>$80.00</td>
<td>$43.2K</td>
<td align="right">548</td>
<td align="right">86</td>
</tr>
</tbody>
</table>

<h3>About Sarepta Therapeutics</h3>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Having examined the options trading patterns of Sarepta Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Sarepta Therapeutics</h3>
<ul>
<li>With a volume of 1,192,820, the price of SRPT is down -0.2% at $73.3. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 40 days.</li>
</ul>
<h3>What The Experts Say On Sarepta Therapeutics</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $141.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Perform, setting a price target of $105. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $163. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $163. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $202. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Sell, setting a price target of $75. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Sarepta Therapeutics

Press Releases

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

Legal

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. – SRPT

ADMA Biologics

Alkermes

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Vaxcyte

PTC Therapeutics

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Piper Sandler

HC Wainwright & Co.

Morgan Stanley

Wells Fargo

Needham

화요일(18일) 미국 증시는 투자자들이 <a href="https://in.benzinga.com/government/regulations/25/03/44364688/feds-march-meeting-expected-to-signal-no-hurry-on-rate-cuts-as-powell-likely-to-tread-carefully" target="_blank" rel="noopener">연준의 금리 결정</a>을 기다리면서 하락했다. 다우존스 산업평균지수는 0.6% 하락한 41,581.31포인트에 마감했고, S&amp;P 500 지수는 거의 1.1% 하락한 5,614.66포인트에 거래를 마쳤다. 나스닥은 1.7% 하락하여 17,504.12포인트에 마감했다.
화요일에 소매 투자자와 트레이더의 주목을 받은 주요 주식은 다음과 같다.
<h3>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</h3>
화요일 엔비디아 주가는 3.43% 하락하여 115.43달러에 마감했다. 주가는 장중에 119.02달러로 최고가를 기록했으며, 최저가는 114.54달러였다. 52주 주가 범위는 75.61~153.13달러다. 엔비디아 CEO인 젠슨 황은 엔비디아의 블랙웰 기반 AI 기술을 자율주행 및 제조에 통합하기 위해 <a href="https://www.benzinga.com/tech/25/03/44383445/nvidia-ceo-jensen-huang-announces-gm-partnership-the-time-for-autonomous-vehicles-has-arrived" target="_blank" rel="noopener">GM과 파트너십</a>을 맺었다고 발표했다. 또한 GTC 2025에서 황은 "피지컬 AI"의 부상과 다양한 산업에서 엔비디아의 역할이 커지고 있음을 강조했다.
<h3>메타 플랫폼스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</h3>
메타의 주가는 3.73% 하락하여 582.36달러로 마감했으며, 장중 최고가는 600.25달러, 최저가는 574.66달러였다. 주가의 52주 최고가와 최저가는 각각 740.89달러 및 414.5달러다. 울프 리서치의 애널리스트들은 메타가 현재 시장에서 저평가된 <a href="https://in.benzinga.com/markets/25/03/44374847/meta-could-rake-in-30-40-billion-in-revenue-from-whatsapp-business-messaging-predicts-analyst" target="_blank" rel="noopener">비즈니스 메시징 서비스</a>에서 300억~400억 달러의 매출을 올릴 수 있을 것으로 예상하고 있다.
<h3>사렙타 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)</h3>
사렙타의 주가는 27.44% 급락해 최고가 81.87달러, 최저가 73.06달러로 마감하며 52주 신저가를 기록했다. 이러한 하락은 듀센 근이영양증에 대해 유일하게 승인된 치료법인 <a href="https://in.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" target="_blank" rel="noopener">엘리비디스(Elevidys) 유전자 치료제</a>로 치료 후 환자가 사망했다는 회사의 보고 이후 나왔다.
<h3>D-웨이브 퀀텀 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)</h3>
D-웨이브 퀀텀 주가는 3.40% 하락하여 10.80달러로 마감했으며, 최고가는 11.50달러, 최저가는 9.48달러였다. 52주 범위는 0.75~11.50달러다. GPU 기술 컨퍼런스의 일환인 엔비디아의 퀀텀 데이를 앞두고 <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44385434/d-wave-quantum-shares-traded-lower-tuesday-what-happened" target="_blank" rel="noopener">양자 주식</a>이 변동성에 직면하면서 하락세를 보였다.
<h3>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</h3>
테슬라의 주가는 5.34% 하락하여 225.31달러로 마감했으며, 장중 최고가 230.10달러, 최저가 222.28달러를 기록했다. 52주 범위는 138.80~488.54달러다. 그러나 일론 머스크가 이끄는 테슬라의 주가는 시간외 거래에서 거의 1.1 % 상승했다. 정규 거래의 하락은 엔비디아와 제너럴 모터스가 자율주행 차량에 대한 파트너십을 발표하면서 테슬라의 시장 지위에 영향을 미쳤기 때문에 발생했다.
<a href="https://www.benzinga.com/premarket">벤징가 프리마켓 주요 동향 및 뉴스</a>와 함께 오늘의 거래를 준비하세요.
이미지 출처: Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) 주식은 지난주 65.57% 급등했다.
2. 스칼러 락 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) 주식은 경쟁사인 바이오헤이븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)의 척수성 근위축증에 대한 탈데프그로베프(taldefgrobep)가 <a href="https://www.benzinga.com//node/42169246" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3상 연구에 실패한 후</a> 주가는 49.61% 급등했다.
3. 애로우헤드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) 주식은 사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)와 여러 임상 및 전임상 siRNA 프로그램에 대한 글로벌 라이선스 및 협력 계약을 체결한 후 42.40% 상승했다.
4. 아이리스 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) 주식은 회사가 1분기 실적을 발표하고 여러 애널리스트가 주가 전망을 상향 조정한 후 38.99% 급등했다.
5. 힘스 앤 허스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) 주식은 대통령 당선인 도널드 트럼프가 마티 마카리(Marty Makary)를 식품의약국(FDA) 수장으로 지명할 계획을 발표한 후 33.42% 상승했다.
6. 사운드하운드 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) 주식은 33.38% 상승했다. 이 회사는 최근 <a href="https://www.benzinga.com//node/42145826" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">AEMA 그룹의 일부로 아피비아 쿠르타주</a>(Apivia Courtage)에 대화형 AI 에이전트인 아멜리아(Amelia)를 배포했다고 발표했다.
7. 조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) 주식은 토요타 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>)가 이 회사에 5억 달러를 투자했다는 발표 후 31.62% 상승했다.
8. 어번 아웃피터스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) 주식은 회사가 3분기 실적을 발표하고 여러 애널리스트가 주가 전망을 상향 조정한 후 30.43% 상승했다.
 
또한 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B9%84%EC%95%88-%EB%A1%9C%EC%BC%93%EB%9E%A9-%EB%B0%8F-%EB%AA%A8%EB%8D%94%EB%82%98%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EA%B7%B8%EB%9E%A9-%EB%B0%8F-%EC%98%A4%ED%86%A0%EB%8D%B0%EC%8A%A4%ED%81%AC-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-11/" target="_blank" rel="noopener">레딧, 그랩 및 오토데스크 지난주 최악의 성과를 보인 11개 대형주 중 일부 (11월 25일-29일)</a></li>
</ul>
이미지 출처: Archer


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 22.06% 급등했다. 이는 회사가 <a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener">66억 달러의 에너지부(DOE)의 대출 약정</a>을 확보한 후 발생한 일이다.
2. 로켓랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">뉴멕시코 주에서 반도체 운영을 강화하기 위한 2,390만 달러의 칩스(CHIPS) 법안 지원금</a>을 확보한 후 21.73% 상승했다.
3. 사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)의 주식이 20.67% 상승했다. 이는 회사가 애로우헤드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>)와 <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">여러 임상 및 비임상 siRNA 프로그램</a>에 대한 글로벌 라이선스 및 협력 계약을 발표한 후 발생한 일이다.
4. 이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)의 주식이 16.98% 상승했다. 이는 메디케어 및 메디케이드 서비스 센터가 <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025년 임상 실험실 수수료 일정</a>에 대한 최종 지급 결정을 발표한 후 발생한 일이다.
5. 엘라스틱 N.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>)의 주식이 16.29% 상승했다. 웨드부시 증권의 애널리스트인 댄 아이브스가 인공지능(AI) 혁명의 다음 단계에 대한 낙관론을 크게 높인 후 발생한 일이다. 그는 소프트웨어 분야에 대한 <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">변혁적 영향을 강조</a>했다.
6. 울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)의 주식이 14.13% 상승했다. 이는 씨티그룹의 애널리스트들이 주식의 <a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 상향 조정</a>한 후 발생한 일이다.
7. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식이 지난 주 12.58% 급등했다.
8. 랄프 로렌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>)의 주식이 지난 주 11.72% 상승했다.
9. 코파트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>)의 주식은 회사가 예상보다 좋은 1분기 매출 실적을 발표한 후 11.41% 상승했다.
10. 스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>)의 주식이 12.18% 상승했다. 이는 씨티그룹의 애널리스트들이 주식의 <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 상향 조정</a>한 후 발생한 일이다.
 
사진 출처: rblfmr via Shutterstock


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>맥케슨 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)의 주가는 예상보다 나쁜 FY25 <a href="https://www.benzinga.com//node/40232820" target="_blank" rel="noreferrer noopener">1분기 매출 실적</a>을 보고한 후 12.06% 하락했다. 분석가들은 회사의 <a href="https://www.benzinga.com/quote/mck/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 수정했다.</li>
<li>바이오-테크네(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>)는 예상보다 나쁜 4분기 매출 결과로 지난주 주가가 11.71% 하락했다.</li>
<li>워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주가는 부진한 <a href="https://www.benzinga.com//node/40234107" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>에 따라 10.62% 하락했다. 몇몇 분석가들은 주식에 대한 등급과 <a href="https://www.benzinga.com//node/40264035" target="_blank" rel="noreferrer noopener">목표 주가</a>를 업데이트했다.</li>
<li>찰스 리버 래보래토리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)의 주가는 2분기 실적에서 10.41% 하락했고 FY24 <a href="https://www.benzinga.com//node/40222523" target="_blank" rel="noreferrer noopener">조정된</a> 전망도 하향 조정됐다. 애널리스트들은 해당 주식의 <a href="https://www.benzinga.com/quote/crl/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 낮췄다.</li>
<li>사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)의 주가는 예상보다 부진한 2분기 매출로 인해 9.33% 하락했다. 회사는 추정치보다 낮은 FY25 순 제품 매출 지침을 발표했으며 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/srpt/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">가격 예측을 하향 조정</a>했다.</li>
<li>몬스터 베버리지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>)가 <a href="https://www.benzinga.com//node/40233200" target="_blank" rel="noreferrer noopener">2분기 재무 결과</a>를 발표한 후 주가가 8.95% 급락했다. 많은 분석가들이 <a href="https://www.benzinga.com/quote/mnst/analyst-ratings" target="_blank" rel="noreferrer noopener">목표</a> 가격을 하향 조정했다.</li>
<li>탑빌드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>)의 주가는 예상보다 나쁜 <a href="https://www.benzinga.com//node/40182863" target="_blank" rel="noreferrer noopener">분기 실적 결과</a>에 따라 8.93% 하락했다. 몇몇 분석가들은 회사의 <a href="https://www.benzinga.com/quote/bld/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격</a>을 낮췄다.</li>
<li>에어비앤비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>)의 주가는 회사가 예상보다 나쁜 분기별 EPS 실적을 보고하고 예상치보다 낮은 <a href="https://www.benzinga.com//node/40203008" target="_blank" rel="noreferrer noopener"> 3분기 매출 전망</a>을 발표한 후 7.01% 하락했다. 많은 분석가들은 <a href="https://www.benzinga.com//node/40227192" target="_blank" rel="noreferrer noopener">목표</a> 가격을 낮췄다.</li>
<li>어드밴스드 드레이니지 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>)의 주가는 <a href="https://www.benzinga.com//node/40246477" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 실적 부진</a>으로 인해 6.94% 하락했다.</li>
<li>SBA 커뮤니케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>)의 주식은 지난주 6.85% 떨어졌다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%eb%b0%8f-%ed%8c%94%eb%9e%80%ed%8b%b0%ec%96%b4%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-10/" target="_blank" rel="noopener">쇼피파이 및 팔란티어는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 4일-8월 10일)</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ABNB

DELL

MNST

SBAC

SMCI

TECH

워너 브라더스 및 맥케슨은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 4일-8월 10일)

이들 대형주들은 지난주 최고의 성과를 거두었습니다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)의 주가는 회사가 엘리비디스(ELEVIDYS)의 라벨 표시 적응증에 최소 4세 이상의 듀센 <span class="c5aZPb" tabindex="0" role="button" data-enable-toggle-animation="true" data-extra-container-classes="ZLo7Eb" data-hover-hide-delay="1000" data-hover-open-delay="500" data-send-open-event="true" data-theme="0" data-width="250" data-ved="2ahUKEwijqpmq3vKGAxXva_UHHc50CRoQmpgGegQIERAD">근이영양증(DMD) 유전자 돌연변이가 확인된 듀센 근이영양증 환자를 포함하도록 확장하는 것에 대한 미 식품의약국(FDA)의 승인을 발표한 후 29.50% 상승했다. 또한, 여러 투자 은행들이 해당 종목에 대해 <a href="https://www.benzinga.com/quote/srpt/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 목표 주가를 상향 조정</a>했다.</li>
<li>시리우스 XM 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)의 주가는 지난주 16.73% 상승했다.</li>
<li>토스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)의 주가는 지난주 15.57% 상승했다.</li>
<li>길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)의 주가는 <a href="https://www.benzinga.com//node/39435732" target="_blank" rel="noreferrer noopener">긍정적인 3단계 HIV 데이터</a> 이후 지속적인 강세를 보이며 지난주 12.62% 상승했다.</li>
<li>츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주가는 10.59% 상승했다. 이는 5월 <a href="https://www.benzinga.com//node/39385252" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">o온라인 매장에서의 소매 구매가 증가</a>한 후 주가가 올랐을 가능성이 크다.</li>
<li>액센츄어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>)의 회사가 3분기 실적을 <a href="https://www.benzinga.com//node/39410240" target="_blank" rel="noreferrer noopener">발표한 이후</a> 주가는 9.80% 상승했다. 몇몇 분석가들은 가격 예측을 <a href="https://www.benzinga.com/quote/acn/analyst-ratings" target="_blank" rel="noreferrer noopener">하향 조정</a>했습니다.</li>
<li>드래프트킹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)의 주가는 지난주 9.69% 상승했다. 이는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39316935/draftkings-stock-can-overcome-wall-of-worry-around-various-regulatory-risks-analyst">6월 30일까지 최종 확정되어야 할 뉴저지 2025년 예산안에 세금을 도입하지 않을 것으로 예상되어, 플로리다의 온라인 스포츠 베팅의 미래에 중대한 영향을 미칠 결정에 따른 주가 상승으로 보입니다.</a></li>
<li>이러한 급증은 플로리다 온라인 스포츠 베팅의 미래에 중요한 영향을 미치는 미국 대법원의 중추적 결정과 6월 30일까지 확정되어야 하는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39316935/draftkings-stock-can-overcome-wall-of-worry-around-various-regulatory-risks-analyst">뉴저지의 2025년 예산에 세금</a>이 도입되지 않을 것이라는 낙관론에 따른 것이다.</li>
<li>델(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)의 주가는 일론 머스크가 회사의 xAI가 구축하고 있는 슈퍼컴퓨터에 들어갈 이 랙의 절반을 조립하고 있다고 <a href="http://dell%20shares%20are%20trading%20higher%20after%20elon%20musk%20said%20the%20company%20is%20assembling%20half%20of%20the%20racks%20that%20are%20going%20into%20the%20supercomputer%20that%20xai%20is%20building./" target="_blank" rel="noopener">말한</a> 후 지난주 8.19% 상승했다.</li>
<li>오토데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>)의 주가는 스타보드(Starboard)가 이 회사의 지분을 5억 달러 보유하고 있다고 <a href="https://www.benzinga.com//node/39357211">보도된 이후</a> 7.99% 상승했다.</li>
<li>골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주가는 7.15% 상승했다. <a href="https://www.benzinga.com//node/39416585" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">금값 상승 속</a>에 금 광산주 주가가 상승세를 보이고 있다.</li>
</ol>
사진제공: 셔터스톡
다음 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

ADSK

CELH

CHWY

DKNG

GILD

SIRI

TOST

드래프트킹스와 델은 지난주 최고의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)

목요일 아침(현지 시간 기준) 미국 주식 선물이 더 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li><a href="https://pro.benzinga.com/dashboard">벤징가 프로</a>의 데이터에 따르면 월스트리트에서는 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)이 시장 마감 후 분기별 이익을 주당 1.50달러, 매출 900억 1천만 달러로 보고할 것으로 예상된다. 애플 주가는 시간외 거래에서 1.09% 상승한 171.14달러에 거래되었다.</li>
<li>아르셀로미탈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>)은 1분기에 예상 이상의 실적을 발표하였다. 수요일 아셀로미탈은 tlrksdhl rjfodptj 1.72% 상승하여 25.50달러에 도달했다.</li>
<li>분석가들은 코노코필립스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>)가 매출 150.5억달러에 주당 2.04달러의 분기 이익을 발표할 것으로 예상하고 있다. 이 회사는 시장 개장 전에 실적을 발표할 예정이다.</li>
</ul>
여기를 클릭해 <a href="https://www.benzinga.com/premarket/">프리마켓 동향</a>을 확인하세요.
<ul>
<li>사렙타 테라퓨릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)은 수요일 1분기에 대한 낙관적인 결과를 발표했다. 이 회사는 1주당 73센트의 조정된 이익과 4억 1,346.4만 달러의 매출을 기록했다. 사렙타 테라퓨틱스는 시간외 거래에서 5.92% 상승한 138.65달러에 거래되었다.</li>
<li>분석가들은 켈라노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>)가 목요일 시장 개장 전 주당 85센트의 분기 이익과 매출 31.6억달러에 기록할 것으로 예상하고 있다. 켈라노바는 시간외 거래에서 1% 상승한 57.57달러에 거래되었다.</li>
</ul>

Comments

Sarepta Therapeutics

뉴스

에 대한 최신 뉴스 Sarepta Therapeutics (NASDAQ:SRPT) 주식

수요일, 3월 19, 2025

일요일, 12월 01, 2024

일요일, 8월 11, 2024

일요일, 6월 23, 2024

목요일, 5월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌